DUOPHARMA BIOTECH BERHAD

KLSE: 7148 (DPHARMA)

Last update: 1 hour ago

1.47

0.01 (0.68%)

  • 1D 0.68%
  • 5D 0.00%
  • 1M 6.52%
  • 6M 7.30%
  • YTD 18.55%
  • 1Y 22.50%
  • 5Y -28.19%
Previous Close 1.46
Open 1.46
Volume 255,400
Avg. Volume (3M) 749,620
Market Cap 1,414,055,424
Price / Earnings (TTM) 16.33
Price / Earnings (Forward) 14.14
Price / Sales 1.55
Price / Book 1.87
52 Weeks Range
1.07 (-27%) — 1.57 (6%)
TTM Dividend Yield 3.10%
Profit Margin 8.26%
Operating Margin (TTM) 14.69%
Diluted EPS (TTM) 0.080
Quarterly Revenue Growth (YOY) 36.20%
Quarterly Earnings Growth (YOY) 67.80%
Total Debt/Equity (MRQ) 70.73%
Current Ratio (MRQ) 3.83
Operating Cash Flow (TTM) 114.27 M
Levered Free Cash Flow (TTM) 53.91 M
Return on Assets (TTM) 5.22%
Return on Equity (TTM) 10.48%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (MY) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock DPHARMA Bullish Bullish

AIStockmoo Score

0.2
Analyst Consensus 3.0
Insider Activity -3.5
Price Volatility -5.0
Technical Moving Averages 2.5
Technical Oscillators 4.0
Average 0.20

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
DPHARMA 1 B 3.10% 16.33 1.87
RHONEMA 157 M 3.55% 17.63 0.870
PLABS 72 M - 26.00 0.970

Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Value
% Held by Insiders 2.64%
% Held by Institutions 71.87%

Ownership

Name Date Shares Held
Billion Victory Sdn Bhd 31 Mar 2023 15,070,000 (1.57%)
Manulife Investment Shariah Progress Fund 31 Oct 2022 8,670,000 (0.90%)
52 Weeks Range
1.07 (-27%) — 1.57 (6%)
Price Target Range
1.65 (12%) — 1.72 (17%)
High 1.72 (TA, 17.01%) Buy
Median 1.69 (14.97%)
Low 1.65 (RHB, 12.25%) Buy
Average 1.69 (14.97%)
Total 2 Buy
Avg. Price @ Call 1.52
Firm Date Target Price Call Price @ Call
TA 27 Feb 2026 1.72 (17.01%) Buy 1.49
19 Feb 2026 1.72 (17.01%) Buy 1.55
RHB 19 Feb 2026 1.65 (12.24%) Buy 1.55
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
EMPLOYEES PROVIDENT FUND BOARD - 1.49 -939,100 -1,405,041
LEMBAGA TABUNG HAJI - - 0 0
Aggregate Net Quantity -939,100
Aggregate Net Value ($) -1,405,041
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 1.49
Name Holder Date Type Quantity Price Value ($)
LEMBAGA TABUNG HAJI Substantial Shareholder 02 Mar 2026 Notice of interest 500,000 - -
EMPLOYEES PROVIDENT FUND BOARD Substantial Shareholder 26 Feb 2026 Disposed (-) 200,000 1.47 294,000
EMPLOYEES PROVIDENT FUND BOARD Substantial Shareholder 23 Feb 2026 Disposed (-) 500,000 1.50 750,000
EMPLOYEES PROVIDENT FUND BOARD Substantial Shareholder 20 Feb 2026 Disposed (-) 239,100 1.51 361,041
  • 3M
Date Type Details
04 Mar 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - LEMBAGA TABUNG HAJI
04 Mar 2026 TheEdge Contractors, material firms face cost pressures amid Middle East conflict, CIMB Securities flags
04 Mar 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
03 Mar 2026 TheEdge Tabung Haji emerges as substantial shareholder in Duopharma
03 Mar 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
03 Mar 2026 Announcement Notice of Interest Sub. S-hldr (Section 137 of CA 2016) - LEMBAGA TABUNG HAJI
02 Mar 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
27 Feb 2026 Announcement DPHARMA - Notice of Book Closure
27 Feb 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
26 Feb 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
26 Feb 2026 Announcement Duopharma Biotech maintains robust revenue and profit growth momentum
26 Feb 2026 Announcement Second Interim Dividend
26 Feb 2026 Announcement Quarterly rpt on consolidated results for the financial period ended 31/12/2025
26 Feb 2026 Announcement MATERIAL LITIGATION
26 Feb 2026 TheEdge Duopharma logs record annual profit of RM87.5 mil on resilient demand
26 Feb 2026 TheEdge Duopharma logs record full-year net profit of RM87.5 mil on resilient demand
25 Feb 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
20 Feb 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
19 Feb 2026 TheEdge Duopharma hits three-year high after MOH contract wins for insulin products
19 Feb 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
16 Feb 2026 Announcement ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS THE "LETTER OF AWARD" OR "LOA") FOR THE SUPPLY OF RECOMBINANT HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS THE "PRODUCTS") TO THE GOVERNMENT OF MALAYSIA
16 Feb 2026 TheEdge Duopharma, IGB, MISC, Seal, GDB, Johan Holdings & Farmiera
16 Feb 2026 TheEdge Ministry of Health awards RM65.08 mil contract to Duopharma for distribution of insulin
16 Feb 2026 Announcement ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS THE "LETTER OF AWARD" OR "LOA") FOR THE SUPPLY OF INSULIN INJECTION (HEREINAFTER REFERRED TO AS THE "PRODUCT") BY DUOPHARMA (M) SENDIRIAN BERHAD (A WHOLLY-OWNED SUBSIDIARY OF DUOPHARMA BIOTECH BERHAD) TO THE MINISTRY OF HEALTH'S FACILITIES
13 Feb 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
11 Feb 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
05 Feb 2026 Announcement MATERIAL LITIGATION
03 Feb 2026 Announcement MATERIAL LITIGATION
03 Feb 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
02 Feb 2026 TheEdge Watching for winners and losers of stronger ringgit in corporate earnings
29 Jan 2026 Announcement Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - EMPLOYEES PROVIDENT FUND BOARD
15 Jan 2026 TheEdge Cover Story: Stock picks for 2026 - Navigating opportunities and risks
22 Dec 2025 Announcement MATERIAL LITIGATION
10 Dec 2025 TheEdge Local pharma leap needs government support, says Duopharma’s outgoing chief
Show more
TTM Dividend Yield 3.10%
5Y Average Dividend Yield 2.43%
Payout Ratio 39.53%
Expected Next Dividend Payment Sep 2026
Ex Date Announcement Date Payment Date Details
12 Mar 2026 26 Feb 2026 30 Mar 2026 0.0305 Cash
08 Sep 2025 21 Aug 2025 24 Sep 2025 0.015 Cash
05 Mar 2025 19 Feb 2025 19 Mar 2025 0.02 Cash
29 Aug 2024 15 Aug 2024 12 Sep 2024 0.01 Cash
07 Mar 2024 22 Feb 2024 21 Mar 2024 0.018 Cash
08 Sep 2023 24 Aug 2023 22 Sep 2023 0.005 Cash
07 Apr 2023 27 Mar 2023 09 May 2023 0.018 Cash
29 Aug 2022 16 Aug 2022 14 Sep 2022 0.005 Cash
14 Apr 2022 24 Mar 2022 13 May 2022 0.018 Cash
30 Aug 2021 17 Aug 2021 15 Sep 2021 0.005 Cash
21 Apr 2021 08 Apr 2021 21 May 2021 0.06 Cash
28 Aug 2020 13 Aug 2020 11 Sep 2020 0.005 Cash
13 Jul 2020 30 Jun 2020 12 Aug 2020 0.05 Cash
15 Oct 2019 02 Oct 2019 14 Nov 2019 0.01 Cash
26 Jun 2019 13 Jun 2019 26 Jul 2019 0.04 Cash
02 Nov 2018 22 Oct 2018 23 Nov 2018 0.015 Cash
13 Jun 2018 31 May 2018 17 Jul 2018 0.06 Cash
17 Oct 2017 25 Aug 2017 10 Nov 2017 0.025 Cash
26 May 2017 24 Feb 2017 23 Jun 2017 0.04 Cash
19 Oct 2016 22 Aug 2016 11 Nov 2016 0.025 Cash
06 Jun 2016 23 Feb 2016 28 Jun 2016 0.055 Cash
13 Oct 2015 25 Aug 2015 06 Nov 2015 0.04 Cash
27 May 2015 24 Feb 2015 25 Jun 2015 0.145 Cash
15 Oct 2014 26 Aug 2014 07 Nov 2014 0.04 Cash
22 May 2014 26 Feb 2014 20 Jun 2014 0.135 Cash
14 Oct 2013 28 Aug 2013 08 Nov 2013 0.04 Cash
14 Jun 2013 22 Mar 2013 12 Jul 2013 0.105 Cash
15 Oct 2012 16 Aug 2012 09 Nov 2012 0.035 Cash
06 Jun 2012 16 Mar 2012 29 Jun 2012 0.145 Cash
05 Oct 2011 18 Aug 2011 28 Oct 2011 0.035 Cash
08 Jun 2011 21 Apr 2011 27 Jun 2011 0.11 Cash
06 Oct 2010 02 Sep 2010 28 Oct 2010 0.045 Cash
09 Jun 2010 21 Apr 2010 25 Jun 2010 0.12 Cash
01 Oct 2009 26 Aug 2009 23 Oct 2009 0.06 Cash
10 Jun 2009 15 Apr 2009 26 Jun 2009 0.07 Cash
08 Oct 2008 26 Aug 2008 28 Oct 2008 Interim Dividend
03 Oct 2007 24 Aug 2007 18 Oct 2007 Interim Dividend
29 May 2007 25 Apr 2007 08 Jun 2007 Final Dividend
11 Sep 2006 23 Aug 2006 22 Sep 2006 Interim Dividend
18 May 2006 24 Apr 2006 08 Jun 2006 First and Final Dividend
26 Jul 2005 06 Jun 2005 18 Aug 2005 Final Dividend
21 Oct 2004 06 Oct 2004 08 Nov 2004 Interim Dividend
06 Jul 2004 01 Jun 2004 28 Jul 2004 Final Dividend
26 Sep 2003 09 Sep 2003 20 Oct 2003 Interim Dividend
23 Jun 2003 25 Apr 2003 08 Jul 2003 First and Final Dividend
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2026 0.031 1 2.09
2025 0.035 2 2.80
2024 0.028 2 2.24
2023 0.023 2 1.83
2022 0.023 2 1.43
2021 0.065 2 3.87
2020 0.055 2 2.17
2019 0.050 2 4.70
2018 0.075 2 10.53
2017 0.065 2 7.99
2016 0.080 2 12.57
2015 0.185 2 21.97
2014 0.175 2 29.38
2013 0.145 2 23.59
2012 0.180 2 35.47
2011 0.145 2 30.13
2010 0.165 2 28.97
2009 0.130 2 23.22
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria